活检前磁共振成像路径在前列腺癌诊断中的临床实施
这项两中心回顾性队列研究评估了活检前磁共振成像(MRI)路径在常规临床实践中用于疑似前列腺癌初诊男性的效果。共纳入2597例男性,57%因MRI不 suspicious 而避免活检;经逆概率加权后,经直肠与经会阴MRI引导活检对Grade Group≥2和≥3癌症的检出率及并发症率相当。
要点
- 活检前MRI作为决策工具可在日常实践中实施,57%的男性避免了活检。
- 经直肠与经会阴MRI引导活检的癌症检出率和并发症率相当。
- 该路径未损害Grade Group≥2/≥3癌症检出,且Grade Group 1过度检出率较低。
核心结论
- 在高容量两中心研究中,活检前MRI作为决策工具可实施于日常临床实践。
- 与近期试验相比,实现了更高的活检避免率,且未损害Grade Group≥2/≥3检出,同时Grade Group 1过度检出率更低。
- 经直肠与经会阴MRI引导活检的前列腺癌检出率和并发症率相当。
研究设计与样本
- 两中心回顾性队列,连续纳入2597例疑似前列腺癌的初诊男性,于2015年至2019年在单一高容量中心(中心1)接受符合PI-RADS v2的活检前MRI。
- MRI可疑者:中心1行经直肠MRI引导活检(TR-MRDB),中心2行经会阴MRI引导活检(TP-MRDB)并附加随机活检(RB);MRI和病理均由中心1评估。
- 为减少混杂偏倚,对年龄、直肠指检、前列腺特异性抗原(PSA)、前列腺体积、PSA密度和PI-RADS分类进行逆概率加权(IPW)。
主要发现
- 2597例男性中,总体Grade Group 1、≥2、≥3癌症患病率分别为8%(210/2597)、27%(697/2597)、15%(396/2597)。
- 57%(1488/2597)的男性避免了活检。
- IPW后,TR-MRDB与TP-MRDB的Grade Group 1检出率分别为24%和18%(平均差异-5.7%,95%CI -13%至1.4%)。
- IPW后,TR-MRDB与TP-MRDB的Grade Group≥2检出率分别为57%和64%(平均差异6.1%,95%CI -2.1%至14%)。
- IPW后,TR-MRDB与TP-MRDB的Grade Group≥3检出率分别为32%和38%(平均差异5.7%,95%CI -1.7%至13%)。
临床怎么用
- 活检前MRI可作为疑似前列腺癌初诊男性的决策工具,以减少不必要的活检。
- 经直肠与经会阴MRI引导活检均可选择,两者癌症检出率和并发症率相当。
局限性
- 回顾性两中心队列设计,中心间活检路径不同(经直肠 vs 经会阴附加随机活检)。
- 虽采用逆概率加权减少混杂,但仍可能存在未测量偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the outcomes of pre-biopsy magnetic resonance imaging (MRI) pathways, as a tool in biopsy-naïve men with suspicion of prostate cancer, in routine clinical practice. Secondary outcomes included a comparison of transrectal MRI-directed biopsy (TR-MRDB) and transperineal (TP)-MRDB in men with suspicious MRI. PATIENTS AND METHODS: We retrospectively assessed a two-centre cohort of consecutive biopsy-naïve men with suspicion of prostate cancer who underwent a Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2) compliant pre-biopsy MRI in a single, high-volume centre between 2015 and 2019 (Centre 1). Men with suspicious MRI scans underwent TR-MRDB in Centre 1 and TP-MRDB with additional random biopsies (RB) in Centre 2. The MRI and histopathology were assessed in the same institution (Centre 1). Outcomes included: (i) overall detection rates of Grade Group (GG) 1, GG ≥2, and GG ≥3 cancer in men with suspicious MRI; (ii) Biopsy-avoidance due to non-suspicious MRI; and (iii) Cancer detection rates and biopsy-related complications between TR- and TP-MRDB. To reduce confounding bias for MRDB comparisons, inverse probability weighting (IPW) was performed for age, digital rectal examination, prostate-specific antigen (PSA), prostate volume, PSA density, and PI-RADS category. RESULTS: Of the 2597 men included, the overall GG 1, GG ≥2, and GG ≥3 prevalence was 8% (210/2597), 27% (697/2597), and 15% (396/2597), respectively. Biopsy was avoided in 57% (1488/2597) of men. After IPW, the GG 1, GG ≥2 and GG ≥3 detection rates after TR- and TP-MRDB were comparable at 24%, 57%, and 32%; and 18%, 64%, and 38%, respectively; with mean differences of -5.7% (95% confidence interval [CI] -13% to 1.4%), 6.1% (95% CI -2.1% to 14%), and 5.7% (95% CI -1.7% to 13%). Complications were similar in TR-MRDB (0.50%) and TP-MRDB with RB (0.62%; mean difference 0.11%, 95% CI -0.87% to 1.1%). CONCLUSION: This high-volume, two-centre study shows pre-biopsy MRI as a decision tool is implementable in daily clinical practice. Compared to recent trials, a substantially higher biopsy avoidance rate was achieved without compromising GG ≥2/GG ≥3 detection and coinciding with lower over detection rates of GG 1 cancer. Prostate cancer detection and complication rates were comparable for TR- and TP-MRDB.
引用
- Israël B, Immerzeel J, van der Leest M, et al. Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer. BJU Int. 2021. PMID: 34358388. doi:10.1111/bju.15562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。